Inactive Instrument

Acacia Pharma Group plc Stock price

Equities

ACPH

GB00BYWF9Y76

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 15-07-31
Chairman 54 15-02-28
Chief Tech/Sci/R&D Officer - 07-12-31
Members of the board TitleAgeSince
Director/Board Member 65 18-02-28
Director/Board Member 69 18-02-28
Chairman 54 15-02-28
More insiders
Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Acacia Pharma Group plc - Euronext Bruxelles